{
  "story_id": "a1515e32c8da935f93df7c0db2152246",
  "desk": "drm3",
  "revision": 1,
  "published_at": "2026-09-02T18:00:00.000Z",
  "content_hash": "ca424e4972eae693c91d3145734fe505dad11a9fb231252704721476ce58a140",
  "hash_basis": "sha256 over `headline\\ndek\\nprose`, plus `\\n` + the canonical citations JSON when any source is placed, plus `\\n#blog` for blogs",
  "basis": {
    "headline": "ENvue Medical Shares Slide on Reverse Split and Macro Weakness",
    "dek": "ENvue Medical stock fell 1.5% as a reverse split took effect amid rising bond yields and geopolitical fears.",
    "prose": "Investing.com reported that ENvue Medical stock slipped 1.5% in morning trading as the company's 1-for-12 reverse stock split became effective. [^1]\n\nOn 2026-08-27, JATT III Acquisition Corp closed its initial public offering of 6.9 million ordinary shares at $10 per share, including the underwriter's full overallotment of an additional 900,000 shares, generating $69 million in gross proceeds before underwriting discounts and offering expenses. [^2]\n\nEvery twelve pre-split shares were combined into one post-split share, reducing outstanding common shares from 11,084,616 to approximately 923,718. [^3]\n\nShares of ENvue Medical commenced post-split trading on the Nasdaq Capital Market under the existing ticker symbol FEED with a new CUSIP number. [^4]\n\nThe company announced the reverse split on August 28, 2026, with the ratio of 1-for-12 set to become effective on September 1, 2026. [^5]\n\nAI Biotechnology LLC, an affiliate of Access Industries, Inc., and Vianti Capital Fund I, L.P. indicated non-binding interests to participate in a private placement that may occur concurrently with JATT III's initial business combination. [^6]\n\nThe JATT III offering included participation from Adage Capital Partners, L.P., ADAR1 Capital, Affinity Asset Advisors, LLC, Columbia Threadneedle Investments, Deep Track Capital, Great Point Partners, LLC, Janus Henderson Investors, Nantahala Capital, RA Capital Management, Sirenia Capital Management LP, Squadron Capital Management LLC, and other institutional investors. [^7]",
    "cited": "[{\"statement\":\"Investing.com reported that ENvue Medical stock slipped 1.5% in morning trading as the company's 1-for-12 reverse stock split became effective.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T14:12:14.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"On 2026-08-27, JATT III Acquisition Corp closed its initial public offering of 6.9 million ordinary shares at $10 per share, including the underwriter's full overallotment of an additional 900,000 shares, generating $69 million in gross proceeds before underwriting discounts and offering expenses.\",\"source\":\"Cision PR Newswire\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T18:00:00.000Z\",\"publisher_count\":1,\"sources\":[\"Cision PR Newswire\"]},{\"statement\":\"Every twelve pre-split shares were combined into one post-split share, reducing outstanding common shares from 11,084,616 to approximately 923,718.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T14:12:14.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"Shares of ENvue Medical commenced post-split trading on the Nasdaq Capital Market under the existing ticker symbol FEED with a new CUSIP number.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T14:12:14.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"The company announced the reverse split on August 28, 2026, with the ratio of 1-for-12 set to become effective on September 1, 2026.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T14:12:14.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"AI Biotechnology LLC, an affiliate of Access Industries, Inc., and Vianti Capital Fund I, L.P. indicated non-binding interests to participate in a private placement that may occur concurrently with JATT III's initial business combination.\",\"source\":\"Cision PR Newswire\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T18:00:00.000Z\",\"publisher_count\":1,\"sources\":[\"Cision PR Newswire\"]},{\"statement\":\"The JATT III offering included participation from Adage Capital Partners, L.P., ADAR1 Capital, Affinity Asset Advisors, LLC, Columbia Threadneedle Investments, Deep Track Capital, Great Point Partners, LLC, Janus Henderson Investors, Nantahala Capital, RA Capital Management, Sirenia Capital Management LP, Squadron Capital Management LLC, and other institutional investors.\",\"source\":\"Cision PR Newswire\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T18:00:00.000Z\",\"publisher_count\":1,\"sources\":[\"Cision PR Newswire\"]}]",
    "kind": "news"
  },
  "receipt_verify": "Ed25519 over the dot-joined string `slice_hash.cursor_from.cursor_to.view.view_version.row_count`; public_key and sig are base64url of the raw 32-byte key / 64-byte signature",
  "receipt": null,
  "receipt_note": "this revision predates receipt-keeping (before v0.37.0); the filed row lives in the record",
  "generation_chain": {
    "wire": {
      "stream": "fountain_news",
      "story_id": "35af3b3385c5e7fcbfb1f40dc2010eae",
      "thread_id": "1174726d985820efd4e633e14ec15ef5",
      "thread_label": "Nasdaq Capital Market",
      "novelty": "UPDATE",
      "content_hash": "c173f6e0f2d7d210e5a872b220584f47ef91c545526b250aecac3e9d4c7848ee",
      "last_published_at": "2026-09-02T18:00:00.000Z",
      "read_receipt": {
        "slice_hash": "11220e4dbf5190921f107dbdea6d99cd844703ff4eef74569640e84ea83ced60",
        "cursor_from": "eyJ0cyI6IjIwMjYtMDktMDJUMTc6NDQ6NDkuMDAwMDAwWiIsImlkIjoiMzY4OTUzMTNmMmQ0NTU3Zjk3Nzk4NTU5NDE1MWQ0OTYiLCJ2IjoiMSJ9",
        "cursor_to": "eyJ0cyI6IjIwMjYtMDktMDJUMTk6NDU6MTcuMDAwMDAwWiIsImlkIjoiMjc4NjE2ZTUxYmJmNDhkYmNlNzZjNjhlYmMxM2E2NmUiLCJ2IjoiMSJ9",
        "view": "v_fountain_news",
        "view_version": "1",
        "row_count": 100,
        "window_days": 3,
        "bytes_scanned": 10113494,
        "credits": 8,
        "price_per_100_rows": 8,
        "sig": "TfMTRUXpx7CzBxHaDv5ngbDuMNWmGAy2xiFXiaO_Paus3_lE3iKiHphYPVaT8Ac2h-vl_QwA11jHegTeg3YTCA",
        "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE",
        "signer_path": "lakehouse/data-extract/v1",
        "alg": "Ed25519",
        "signed": true
      }
    },
    "written_at": "2026-09-03T00:45:54.966Z"
  },
  "cited_facts": [
    {
      "statement": "Investing.com reported that ENvue Medical stock slipped 1.5% in morning trading as the company's 1-for-12 reverse stock split became effective.",
      "source": "Investing.com",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T14:12:14.000Z",
      "publisher_count": 1,
      "sources": [
        "Investing.com"
      ]
    },
    {
      "statement": "On 2026-08-27, JATT III Acquisition Corp closed its initial public offering of 6.9 million ordinary shares at $10 per share, including the underwriter's full overallotment of an additional 900,000 shares, generating $69 million in gross proceeds before underwriting discounts and offering expenses.",
      "source": "Cision PR Newswire",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-02T18:00:00.000Z",
      "publisher_count": 1,
      "sources": [
        "Cision PR Newswire"
      ]
    },
    {
      "statement": "Every twelve pre-split shares were combined into one post-split share, reducing outstanding common shares from 11,084,616 to approximately 923,718.",
      "source": "Investing.com",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T14:12:14.000Z",
      "publisher_count": 1,
      "sources": [
        "Investing.com"
      ]
    },
    {
      "statement": "Shares of ENvue Medical commenced post-split trading on the Nasdaq Capital Market under the existing ticker symbol FEED with a new CUSIP number.",
      "source": "Investing.com",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T14:12:14.000Z",
      "publisher_count": 1,
      "sources": [
        "Investing.com"
      ]
    },
    {
      "statement": "The company announced the reverse split on August 28, 2026, with the ratio of 1-for-12 set to become effective on September 1, 2026.",
      "source": "Investing.com",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T14:12:14.000Z",
      "publisher_count": 1,
      "sources": [
        "Investing.com"
      ]
    },
    {
      "statement": "AI Biotechnology LLC, an affiliate of Access Industries, Inc., and Vianti Capital Fund I, L.P. indicated non-binding interests to participate in a private placement that may occur concurrently with JATT III's initial business combination.",
      "source": "Cision PR Newswire",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-02T18:00:00.000Z",
      "publisher_count": 1,
      "sources": [
        "Cision PR Newswire"
      ]
    },
    {
      "statement": "The JATT III offering included participation from Adage Capital Partners, L.P., ADAR1 Capital, Affinity Asset Advisors, LLC, Columbia Threadneedle Investments, Deep Track Capital, Great Point Partners, LLC, Janus Henderson Investors, Nantahala Capital, RA Capital Management, Sirenia Capital Management LP, Squadron Capital Management LLC, and other institutional investors.",
      "source": "Cision PR Newswire",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-02T18:00:00.000Z",
      "publisher_count": 1,
      "sources": [
        "Cision PR Newswire"
      ]
    }
  ],
  "note": "A signature proves who filed this and that it has not changed since. It never makes a claim true."
}